Navigation Links
NanoPass Makes its MicronJet Technology Available to Increase Global Supply of Pandemic Influenza Vaccines

NES ZIONA, Israel, August 13 /PRNewswire/ -- Following the World Health Organization (WHO) declaration of a swine flu pandemic,[1] NanoPass Technologies Ltd. (NanoPass) announced today that it has successfully developed a microneedle-based injection device that could dramatically enhance both the effectiveness and supply of pandemic flu vaccines.

"As declared by WHO on June 11th, 2009", said Dr Yotam Levin, the Company's CEO, "the novel A H1N1 influenza has become a phase 6 global pandemic. There is an imminent need of developing countries, as well as that of many developed countries, for an adequate supply of pandemic flu vaccines. Since global capacity is limited and production yield is reported to be low, novel approaches for vaccine enhancement are of great need." Dr Ofer Sharon, the Company's Medical Director added, "NanoPass has proven in a randomized clinical trial, recently published in Vaccine,[2] that it can reduce the dose of a seasonal flu vaccine by 80% while preserving its efficacy. This effect is thought to be achieved by targeting the potent specialized immune cells that reside in the skin. This means that health authorities can use the same amount of vaccine they have sourced, to vaccinate at least double, if not triple, the number of subjects, with the same vaccine purchase." NanoPass is designing clinical studies to demonstrate this significant effect for swine H1N1.

The major global public threat posed by the new H1N1 flu strain demands close coordination among vaccine manufacturers, governments, technology developers and global health authorities to manage the supply of vaccines and to ensure there are enough doses for everyone.

About NanoPass's MicronJet Device

MicronJet is a microneedle-based device for intradermal delivery of vaccines. The device allows for consistent, reliable, and simple delivery of the vaccine directly into the skin. It has been shown in multiple clinical trials,[3,4] that injecting a seasonal influenza vaccine directly into the skin harnesses this very potent immune organ, and allows for both the reduction of the dose required for the same immune response ("dose sparing"), as well as the ability to actually potentiate this response, with the use of equivalent doses ("increased immunogenicity").[5]

This approach is being tested for a variety of major diseases that do not yet have an effective vaccine, such as malaria, HIV and tuberculosis.

NanoPass - Transforming device innovation into global health solutions

NanoPass, founded by Dr Shuki Yeshurun, is an Israeli-based private company developing an innovative delivery device for the enhancement of vaccines and other large molecules. The Company has proven efficacy and safety in multiple applications including seasonal flu, insulin delivery and lidocaine for local anesthesia. MicronJet is approved for marketing in the EU (please see for more information), and is about to be registered in additional markets. The MicronJet is approved for use by health care professionals for intradermal delivery of drugs and medicinal products that are approved for intradermal delivery.


    (Due to the length of this URL, it may be necessary to copy and paste
     this hyperlink into your Internet browser's URL address field. Remove
     the space if one exists.)

    [2] Van Damme P, Oosterhuis-Kafeja F, Van der Wielen M, Almagor Y, Sharon
        O and Levin Y. Safety and efficacy of a novel microneedle device
        for dose sparing intradermal influenza vaccination in healthy adults.
        Vaccine. 2009 Jan 14;27(3):454-9.

    [3] Belshe RB, Newman, FK et al. Serum Antibody Responses after
        Intradermal Vaccination against Influenza. N Engl J Med

    [4] Kenney RT, Frech SA et al. Dose sparing with intradermal injection of
        influenza vaccine. N Engl J Med. 2004 Nov 25;351(22):2295-301. Epub
        2004 Nov 3.

    [5] Holland D, Booy R et al. Intradermal influenza vaccine administered
        using a new microinjection system produces superior immunogenicity in
        elderly adults: a randomized controlled trial. JID 2008; 198:650-58.

Contact: Yotam Levin: +972-8-9313099 or +972-523-392727 or

SOURCE NanoPass Technologies LTD.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Smart Technology Makes Patient Data Collection Easier, More Efficient
2. WeissComm Partners Makes 10 New Hires as It Wins New Accounts and Grows Existing Business
3. Independence Blue Cross Makes Music for Members Ears
4. A Place for Mom COO Makes Seattles 40 Under 40 List
5. Sesame Street Exhibition Makes Texas Premier at The Health Museum
6. Study makes progress in zoning in on biomarkers for better colon cancer treatment
7. New Online Tool Makes Enrollment in Blue Cross of California Easier
8. 1-800-PACK-RAT Makes a Splash During Annual Walk for Hope
9. Eye on Safety Makes Halloween Less Scary
10. An Industry First: New Cooper Health Company Makes Group Employee Benefits Consulting and Wellness Program Design a Package Deal
11. Michigan State Medical Society Foundation Makes A Difference by Assisting Those in Crisis Shelters
Post Your Comments:
(Date:11/25/2015)... ... November 25, 2015 , ... Additional breast cancers found ... mammography, according to a study published online in the journal Radiology. Researchers said ... may necessitate a change in treatment. , Breast MRI is the most sensitive ...
(Date:11/25/2015)... ... November 25, 2015 , ... Medical Solutions, one of ... its stellar workplace culture with the company’s Cincinnati office being named a finalist ... office was named a finalist in Cincinnati Business Courier’s 13th annual Greater Cincinnati ...
(Date:11/25/2015)... ... , ... On November 10, 2015, Bohrer Brady, LLC filed a class and ... a home health care worker who provided companionship services for the elderly, ill or ... by Humana, Inc., Humana at Home, Inc., and SeniorBridge Family Companies (CT), Inc. since ...
(Date:11/25/2015)... ... , ... Dental professionals who would like to become more proficient on their ... Mark Iacobelli’s Advanced Implant Mentoring (AIM) CE course. Courses will be held on December ... of Advanced Implant Mentoring (AIM), Dr. Iacobelli and Dr. D’Orazio are proud to announce ...
(Date:11/25/2015)... (PRWEB) , ... November 25, 2015 , ... On November ... of Tri Lite’s personal heating products business. Cozy Products explains what this ... heaters that fit in well with the Cozy Products business model: to sell personal ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... AVIV, Israel , November 25, 2015 ... (NASDAQ: KTOV ) (TASE: KTOV), a biopharmaceutical company ... simultaneous treatment of various clinical conditions, today announced the ... 3,158,900 American Depository Shares ( ADSs ), each representing ... purchase up to 3,158,900 ADSs. The ADSs and warrants ...
(Date:11/25/2015)... Nov. 25, 2015 Allergan plc (NYSE: ... and Rugen Therapeutics, a start-up  biotechnology company focused ... CNS disorders and funded by the F-Prime Biomedical ... entered into an exclusive collaboration to support the ... Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD). ...
(Date:11/25/2015)... TEL AVIV, Israel , November 25, 2015 /PRNewswire/ ... firms (the "New Investors"), pursuant to which BioLight and ... in BioLight,s IOPtima Ltd. subsidiary ("IOPtima") via a private ... global commercialization of its innovative IOPtimate™ system used in ... a regulatory approval pathway process for the IOPtimate™ system ...
Breaking Medicine Technology: